Resorption of auditory ossicles and hearing loss in mice lacking osteoprotegerin

Bone

Volumn 39, Issue 2, 2006, Pages 414-419

  Kanzaki, Sho ^a   Ito, Masako ^b   Takada, Yasunari ^a   Ogawa, Kaoru ^a   Matsuo, Koichi ^a  

^a KEIO UNIVERSITY   (Japan)

^b NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Auditory ossicles; Bone remodeling; Hearing loss; Osteoclast; Osteoprotegerin

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUDITORY OSSICLE; BONE CONDUCTION; BONE DENSITY; BONE MINERAL; BONE REMODELING; CONTROLLED STUDY; EARDRUM; FEMALE; HEARING; HEARING LOSS; INCUS; INNER EAR; MALLEUS; MIDDLE EAR; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; STAPES;

ACOUSTIC STIMULATION; ANIMALS; BONE RESORPTION; EAR OSSICLES; EVOKED POTENTIALS, AUDITORY, BRAIN STEM; FEMALE; GLYCOPROTEINS; HEARING LOSS; HETEROZYGOTE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OSTEOPROTEGERIN; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; TIME FACTORS;

EID: 33744921357     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2006.01.155     Document Type: Article

References (37)

1. Mallo M. Formation of the middle ear: recent progress on the developmental and molecular mechanisms. Dev. Biol. 231 (2001) 410-419
2. Zhang Z., Zhang X., Avniel W.A., Song Y., Jones S.M., Jones T.A., et al. Malleal processus brevis is dispensable for normal hearing in mice. Dev. Dyn. 227 (2003) 69-77
3. Teitelbaum S.L., and Ross F.P. Genetic regulation of osteoclast development and function. Nat. Rev. Genet. 4 (2003) 638-649
4. Karsenty G., and Wagner E.F. Reaching a genetic and molecular understanding of skeletal development. Dev. Cell 2 (2002) 389-406
5. Franzoso G., Carlson L., Xing L., Poljak L., Shores E.W., Brown K.D., et al. Requirement for NF-κB in osteoclast and B-cell development. Genes Dev. 11 (1997) 3482-3496
6. Grigoriadis A.E., Wang Z.Q., Cecchini M.G., Hofstetter W., Felix R., Fleisch H.A., et al. c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 266 (1994) 443-448
7. Matsuo K., Owens J.M., Tonko M., Elliott C., Chambers T.J., and Wagner E.F. Fosl1 is a transcriptional target of c-Fos during osteoclast differentiation. Nat. Genet. 24 (2000) 184-187
8. Takayanagi H., Kim S., Koga T., Nishina H., Isshiki M., Yoshida H., et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev. Cell 3 (2002) 889-901
9. Matsuo K., Galson D.L., Zhao C., Peng L., Laplace C., Wang K.Z., et al. Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos. J. Biol. Chem. 279 (2004) 26475-26480
10. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Luthy R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89 (1997) 309-319
11. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Mochizuki S., et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 3597-3602
12. Martin T.J., and Sims N.A. Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol. Med. 11 (2005) 76-81
13. Cooper C. Epidemiology of osteoporosis. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. The American Society for Bone and Mineral Research (2003) 307-313
14. Adams P.F., and Benson V. Current estimates from the National Health Interview Survey, 1991. Vital Health Stat. 10 (1992) 1-232
15. Henkin R.I., Lifschitz M.D., and Larson A.L. Hearing loss in patients with osteoporosis and Paget's disease of bone. Am. J. Med. Sci. 263 (1972) 383-392
16. Haboubi N.Y., and Hudson P.R. Factors associated with Colles' fracture in the elderly. Gerontology 37 (1991) 335-338
17. Clark K., Sowers M.R., Wallace R.B., Jannausch M.L., Lemke J., and Anderson C.V. Age-related hearing loss and bone mass in a population of rural women aged 60 to 85 years. Ann. Epidemiol. 5 (1995) 8-14
18. Helzner E.P., Cauley J.A., Pratt S.R., Wisniewski S.R., Talbott E.O., Zmuda J.M., et al. Hearing sensitivity and bone mineral density in older adults: the Health Aging and Body Composition Study. Osteoporos. Int. 16 (2005) 1675-1682
19. Bucay N., Sarosi I., Dunstan C.R., Morony S., Tarpley J., Capparelli C., et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 12 (1998) 1260-1268
20. Mizuno A., Amizuka N., Irie K., Murakami A., Fujise N., Kanno T., et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem. Biophys. Res. Commun. 247 (1998) 610-615
21. Amizuka N., Shimomura J., Li M., Seki Y., Oda K., Henderson J.E., et al. Defective bone remodelling in osteoprotegerin-deficient mice. J. Electron. Microsc. (Tokyo) 52 (2003) 503-513
22. Nakamura M., Udagawa N., Matsuura S., Mogi M., Nakamura H., Horiuchi H., et al. Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption. Endocrinology 144 (2003) 5441-5449
23. Cundy T., Hegde M., Naot D., Chong B., King A., Wallace R., et al. A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. Hum. Mol. Genet. 11 (2002) 2119-2127
24. Whyte M.P., Obrecht S.E., Finnegan P.M., Jones J.L., Podgornik M.N., McAlister W.H., et al. Osteoprotegerin deficiency and juvenile Paget's disease. N. Engl. J. Med. 347 (2002) 175-184
25. Chong B., Hegde M., Fawkner M., Simonet S., Cassinelli H., Coker M., et al. Idiopathic hyperphosphatasia and TNFRSF11B mutations: relationships between phenotype and genotype. J. Bone Miner. Res. 18 (2003) 2095-2104
26. Janssens K., de Vernejoul M.C., de Freitas F., Vanhoenacker F., and Van Hul W. An intermediate form of juvenile Paget's disease caused by a truncating TNFRSF11B mutation. Bone 36 (2005) 542-548
27. Cundy T., Davidson J., Rutland M.D., Stewart C., and DePaoli A.M. Recombinant osteoprotegerin for juvenile Paget's disease. N. Engl. J. Med. 353 (2005) 918-923
28. Roodman G.D., and Windle J.J. Paget disease of bone. J. Clin. Invest. 115 (2005) 200-208
29. Teufert K.B., and Linthicum Jr. F. Paget disease and sensorineural hearing loss associated with spiral ligament degeneration. Otol. Neurotol. 26 (2005) 387-391
30. Huizing E.H., and de Groot J.A. Densitometry of the cochlear capsule and correlation between bone density loss and bone conduction hearing loss in otosclerosis. Acta Otolaryngol. 103 (1987) 464-468
31. Monsell E.M. The mechanism of hearing loss in Paget's disease of bone. Laryngoscope 114 (2004) 598-606
32. Whyte M.P., and Hughes A.E. Expansile skeletal hyperphosphatasia is caused by a 15-base pair tandem duplication in TNFRSF11A encoding RANK and is allelic to familial expansile osteolysis. J. Bone Miner. Res. 17 (2002) 26-29
33. Hughes A.E., Ralston S.H., Marken J., Bell C., MacPherson H., Wallace R.G., et al. Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nat. Genet. 24 (2000) 45-48
34. Zehnder A.F., Kristiansen A.G., Adams J.C., Merchant S.N., and McKenna M.J. Osteoprotegerin in the inner ear may inhibit bone remodeling in the otic capsule. Laryngoscope 115 (2005) 172-177
35. Yano K., Tsuda E., Washida N., Kobayashi F., Goto M., Harada A., et al. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J. Bone Miner. Res. 14 (1999) 518-527
36. Browner W.S., Lui L.Y., and Cummings S.R. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J. Clin. Endocrinol. Metab. 86 (2001) 631-637
37. Ueland T., Brixen K., Mosekilde L., Mosekilde L., Flyvbjerg A., and Bollerslev J. Age-related changes in cortical bone content of insulin-like growth factor binding protein (IGFBP)-3, IGFBP-5, osteoprotegerin, and calcium in postmenopausal osteoporosis: a cross-sectional study. J. Clin. Endocrinol. Metab. 88 (2003) 1014-1018